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Abstract  
Nanoparticle (NP)–protein complexes exhibit the “correct identity” of NP in biological media. 
Therefore, protein–NP interactions should be closely explored to understand and to modulate the 
nature of NPs in medical implementations. This review focuses mainly on the physicochemical 
parameters such as dimension, surface chemistry, the morphology of NPs and influence of 
medium pH on the formation of protein corona and conformational changes of adsorbed proteins 
by different kinds of methods. Also, the impact of protein corona on the colloidal stability of 
NPs is discussed. Uncontrolled protein attachment on NPs may bring unwanted impacts such as 
protein denaturation and aggregation. In contrast, controlled protein adsorption by optimal 
concentration, size, pH and surface modification of NPs may result in potential implementation 
of NPs as therapeutic agents especially for disaggregation of amyloid fibrils. Also, the effect of 
NPs-protein corona on reducing the cytotoxicity and clinical implications such as drug delivery, 
cancer therapy, imaging and diagnosis will be discussed. Validated correlative physicochemical 
parameters for NP–protein corona formation frequently derived from protein corona fingerprints 
of NPs which are more valid than the parameters obtained only on the base of NP features. This 
review may provide useful information regarding the potency as well as the adverse effects of 
NPs to predict their behavior in the in vivo experiments. 
Keywords: Protein corona, Colloidal stability, Aggregation, Amyloid disaggregation, 
Cytotoxicity, Clinical application.  
 
Abrivation keys: Bovaine serum albumin (BSA), circular dichroism (CD), cytochrome c (Cyt c), 
Gold (Au), Human serum albumin (HSA), Mass spectrometry (MS), Nanoparticles (NPs), 
Reactive oxygen species (ROS), Silver (Ag), Sodium dodecyl sulfate electrophoresis (SDS-
PAGE), Superparamagnetic iron oxide NPs (SPIONs), Transmission electron microscopy (TEM). 
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1. Introduction 
A basic understanding of physicochemical properties of NP which impact the adsorption of protein 
is decisive for the design and development of well-characterized nanomaterials. These distinctive 
nanomaterials may be implemented in a number of areas, from sensing, where they can be 
employed for the detection of several biomolecules [1-3], to biomedical engineering, where they 
are utilized for targeted drug delivery to cancerous tissues [4-8]. NPs are very attractive in new 
healthcare implementations such as vaccinations [9, 10], cancer diagnosis and therapy [11-15]. 
NPs display distinctive features in the human body, but there is only a limited knowledge of how 
these NPs interact with cells and biomolecules such as proteins. Depending on the NP dimension, 
pH of the medium, surface chemistry and type of NPs and proteins, proteins can mediate the 
formation of a corona at the external surface of NPs [16-18]. The unique protein coronas of 
differently modified or differently sized NPs affect all features of NP – biological systems 
interactions ranging from induced cytotoxicity to the mechanism of infiltration [19-23]. NPs after 
uptaking by a physiological environment are coated with biomolecules almost spontaneously [24, 
25].  
The long-lived protein or short-lived protein layers adsorbed tightly or weakly on the NP surface 
are considered as the hardest coronas (HC) or softest coronas (SC), respectively [26, 27]. Hard 
protein corona compounds allocate the biological identity of the NPs and coronas trigger NP 
bioactivities such as membrane adhesion, infiltration mechanism, cellular signaling pathways, 
biodistribution, and protection [28-31]. Not only the surface features and dimension of NPs and 
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pH of the medium mediate their behavior in vivo, but also the type of proteins attached on the NP 
[32]. Maintaining or denaturing the native conformations of proteins after the adsorption on the 
NP surface could lead to the different consequences, such as effectiveness or toxicity. Thus, 
exploring the specific protein – NP interactions and the corresponding parameters determining the 
mediated conformational alterations of proteins during interactions are the pivotal features needed 
to explore how the biological systems could react in vivo [33]. Besides the protein corona 
formation, one aspect of the NP fate in biological environments is addressed by their colloidal 
stability. Recent reports suggest that NP aggregation induce a major influence on the NP-cell 
interactions with regard to concentration, cellular uptake and adverse effects  [34]. For example, 
the interactions lipids NPs of different dimension and their surface modification were explored to 
examine the correlation between NP physico- chemical features and NP-cell interactions. It was 
revealed that physicochemical characteristics of NPs alone could not determine the interaction of 
NPs with human cervical cancer cell line (HeLa) [35]. Remarkably, determined protein corona 
fingerprints showed several unregulated protein adsorptions on the plasma membranes of HeLa 
cells [35, 36]. As shown in Figure 1, proteins can alter their structures when binding to NPs and 
these NP induced conformation changes are determined by the physiochemical NP surface 
features, and the pH of the medium.  
In recent years, several studies explained dimension and surface morphology-dependent protein 
conformational changes induced by nanomaterials [37-41]. However, the outcomes of these 
studies were inconclusive. A number of bio-molecular coronas were developed in nanomedicine 
for drug targeting purposes. The quantity of publications relating results of investigations of 
protein coronas has enhanced during the last 6 years (2012–2018) considerably. The majority of 
papers have concentrated on the explorations of protein corona compositions mediated by NP 
characteristics such as dimension, morphology, and surface modification [37-42]. Likewise, 
Experiments show that the most important factors affecting the non-specific binding of corona 
protein to NPs are the shape and size particles, surface charge, hydrophobicity, and the surface 
softness or hardness of NPs (Table 1). As such, some outcomes could be formulated how the 
physicochemical characteristics of NPs influence the protein corona and trigger the conformational 
changes of proteins. This could fill the gap in a detailed exploration of how the NP-protein corona 
could switch on the apoptotic pathways of the cells. For this aim, the main goal of this review is 
to review the advances in NP-protein corona induction in order to correlate the physicochemical 
features of NPs with mediated protein corona formation, protein aggregation, and disaggregation. 
Afterwards, the colloidal stability of NPs in the presence of protein will be reviewed. Finally, the 
effect of NP-protein corona on cytotoxicity will be discussed. Methods that can be employed to 
study the proteins adsorbed on the NP surfaces can be categorized in 3 classes as follows [43]: 
1: Methods determining the NP induced-structural changes of proteins: Fourier-transform infrared 
spectroscopy (FTIR), CD, nuclear magnetic resonance (NMR), X-ray crystallography, and 
surface-enhanced Raman spectroscopy (SERS) 
2. Methods quantifying the protein coronas: Liquid chromatography–mass spectrometry (LC-MS), 
TEM and fluorescence spectroscopy 
3. Methods identifying the protein coronas: SDS-PAGE and MS [43].  
 
2. Size 
It was reported that the essential blood proteins adsorb strongly on the surfaces of the NPs and the 
binding constant (Kb) and the number of binding sites (n), heavily depends on the NPs dimension. 
It was also revealed that the model proteins experience structural changes during associations with 
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the NPs and these NPs-induced conformational changes are more obvious in case of larger NPs. 
Table 2 summarizes the effect of NP size on the protein corona structure. Therefore, it may be 
suggested that adsorption of proteins onto the larger size NPs results in larger perturbations of the 
protein conformations. Also, a typical Langmuir adsorption model is observed for proteins on NPs 
with diffrenet sizes. These results are maybe due to the larger surface curvature of smaller NPs 
and efficient preservation of native protein conformations and subsequent potent efficacy in 
comparison with larger NPs. Also, it was indicated that the diameter of the attached protein layers 
enhances continuously as the NP size increases [44]. AuNPs of different sizes were fabricated and 
their interaction mechanisms with the BSA were explored by fluorescence spectroscopy [45]. 
Experimental outcomes displayed that BSA molecules attached to the metallic surfaces via 
electrostatic binding experience marked quenching of their intrinsic fluorescence and reduction of 
the quantum yield of a protein is unique for each NP dimensions. Indeed, reduction of the quantum 
yield is higher in the case of smaller AuNPs [45]. 
The AuNPs-induced structural alterations of bovine heart Cyt c of different dimensions were 
investigated by biophysical approaches [46]. The results displayed in different conformational 
changes of Cyt c upon interaction with AuNPs of different dimension due to the various linkages 
between protein and NPs. It was reported that the AuNP surface induces the NP-mediated 
conformational changes of the adsorbed Cyt c. More folded structure observed when Cyt c 
interacted with smaller AuNPs than that adsorbed on larger AuNPs, and the activity of Cyt c 
attached on the smaller AuNPs was higher than that attached on larger AuNPs [46]. The 
electrostatic interactions were demonstrated to be mainly the crucial determining factor leading to 
the formation of Cyt c/16-nm AuNPs complex, whereas the hydrophobic interactions were 
deduced to be  the leading forces in the adsorption of Cyt c on 2-4 nm AuNPs (Fig. 2). 
NP dimensions and their binding to plasma proteins mediate the prolonged circulation of NPs in 
the bloodstream, which can be considered for therapeutic potency. An approximate magnifying of 
AuNP hydrodynamic dimension was reported after incubation of AuNP with different sizes in 
human plasma [47]. The zeta potential of the 30 nm and 50 nm were reduced significantly after 
incubation with plasma proteins. The plasma proteins adsorbed onto the AuNPs were separated by 
2D SDS-PAGE and identified by MS which revealed a higher abundance on the 30-nm particles 
[47].  
 
3. pH 
The conformational changes of proteins upon interaction with NPs were explored in detail by 
various spectroscopic approaches [48]. It was well documented that proteins in the complex 
experiences marked structural alterations of both secondary and tertiary conformation [48]. 
Changes in the pH of the environment may result in more or less corona protein binding to 
nanomaterials, by changing the protein pattern. Since, nanomaterials with protein corona coverage, 
in absorbing paths, are exposed to a variety of pH conditions, it is necessary to investigate the 
pattern of corona protein in the biological fluids of the blood (neutral pH), intracellular fluid (pH 
6.8) and lysosomes (pH 4.5-5) [49]. The outcome determined that the pH of the system 
substantially affected the structural changes of proteins and that fluorescence and CD studies 
showed that the induced denaturation was even more pronounced at basic pH [48] (Fig. 3). Table 
3 summarizes the effects of medium pH on the adsorption behavior of proteins. Based on the 
reported data, it may be suggested that NPs which are substituted with different moieties and 
different bonds (chemical, electrostatic, etc.) could be applied in pH- controlled release system. 
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PH-sensitive NP-protein conjugates can be tuned by incorporating acid or base-cleavable bonds 
for application in prolonged smart drug delivery systems. 
The adsorption and conformation of proteins on NPs were explored by different methods [50]. The 
AuNP and silica NPs size distributions revealed a greater enhance due to interactions with BSA at 
acidic pHs in comparison with basic pHs (3.4−7.3). These larger NPs sizes triggered reversible 
unfolding of BSA at acidic pH. Over the acidic pH range, the size distribution of the BSA/AuNPs 
or silica NPs complex remains almost unchanged, indicating the structural stability of BSA over 
this pH range [49, 50]. Analogously, Givens, Xu, Fiegel and Grassian [42] by applying silicon NPs 
with albumin coating in various pH environments (range of 2 to 8), showed that the highest 
absorption of albumin by silicon nanoparticles was at pH 3.7, which is close to the isoelectric point 
of the silicon-albumin NPs. They also reported that the structure of BSA absorbed from the original 
BSA is different, but by changing the pH environment from 2 to the neutral, the structure of the 
BSA adsorbed to the original state is reversible. 
 
4. Surface chemistry 
The physicochemical reaction between bio-molecules and NPs are dependent on surface features 
of the NPs. The effect of NPs with positive, negative charges and neutral on the structure of Cyt c 
was investigated [51]. CD spectroscopy showed that changing the NP charges altered markedly 
the conformational stability of adsorbed protein. Indeed, protein retained its native structure upon 
interaction with neutral moieties, but experienced large folding changes on the surfaces of charged 
NPs (Fig. 4) [51]. This is explained by the electrostatic interactions of charged residues and 
ligands. Zwitterionic NPs of variable hydrophobicity showed no induction of hard coronas at 
physiological serum concentrations (Fig. 5) [52]. These NPs can be implemented as potential 
candidates to explore nanobiological fate such as cell infiltrate and membrane damage mediated 
directly by chemical moieties on the NP surface. 
Citrate groups with negative charges at physiological pH, have been employed to functionalize the 
surface of particles, in particular for Au [53-55], Ag [55, 56] and oxide NPs [57-59]. In the 
presence of serum protein, the citrate-modified NPs lost their colloidal stability [53, 54, 56-60]. 
The colloidal destabilization kinetics of citrate capped magnetic NPs in cell culture medium 
without serum was attributed to their complexation with counterions. Serum protein due to 
formation of protein corona delayed the aggregation of NPs [58, 59].  To decrease the protein 
corona impacts, reports have exhibited that neutral polymers or polysaccharides are efficient [61]. 
Tethered at the NP surface by the chain extremity, the polymers form a swollen brush that provides 
a protective layer against protein attachment. A number of approaches based on physical or 
chemical binding are now attainable, including spontaneous adsorption, layer-by-layer deposition 
or surface-induced polymerization. Non-covalent reactions by the assembly of separate parts (e.g. 
NPs, ligands, polymers) reveal increased yields based on the quantity of NPs fabricated and are 
prone for implementations [62]. Recent studies have exhibited that PEGylated NPs from oxides or 
noble metals [60, 63-67] demonstrate reduced protein adsorption. By comparing identical core 
NPs with different surface moieties, it was displayed that the optimum conditions for mitigating 
the protein corona are PEG chain with densities around 1 nm-2 and molecular weight between 2000 
and 10000 g mol-1 [64, 67, 68]. The exact mechanisms of the protein corona on polymer brushes 
have not been elucidated yet. Table 4 outlines the impact of surface modification of NPs on the 
adsorption behavior of proteins. 
It was deduced that, the surface heterogeneity of NPs allows the protein to adopt different 
conformations during interaction. In the case of NPs with negative charge groups, positively-
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charged side chains form electrostatic interactions with the negatively-charged moieties on the NP 
surface, while nonpolar side chain clusters may bind with the nonpolar sites on the surface of NPs. 
Overall, the results of this part indicated that nanoscale manipulations of NP surfaces play a vital 
role in controlling of the NP-protein adsorption. 
 
5. Morphology  
The interaction of NPs with proteins also depends on the morphology of NPs. The effect of NP 
morphology on the conformational changes of lysozyme and α-chymotrypsin was explored [69]. 
It was revealed that proteins ligands more adsorb on the surface of Au nanorods when compared 
with Au nanospheres. Because of raising lateral interactions on the comparatively ‘flat’ cylindrical 
surface may enable a higher packing concentration of proteins adsorbed on Au nanorods in 
comparison with Au nanospheres. After the interaction of lysozyme with Au nanospheres and Au 
nanorods, the more secondary structure was determined after interaction with Au nanorods relative 
to Au nanospheres, causing to complex aggregation and resulting remarkably decreased enzymatic 
activity. ChT retained its secondary conformation and subsequent activity during interactions with 
Au nanorods and Au nanospheres. Therefore, it was suggested that AuNP morphology as well as 
the kind of proteins influence the adsorbed protein folding [69]. 
Spherical AuNPs and flat Au films were fabricated with yeast Cyt C covalently attached to the Au 
surface. Upon exposure to different pH values, it was revealed that Cyt C denatures at acidic pH 
and refolds at basic pH irrespective of the morphology of NPs [70]. The binding between BSA and 
spherical or nanorod AuNP was characterized by different optical spectroscopy approaches. There 
was a superior adsorption of BSA to the two ends of the Au nanorods. The binding assay showed 
that the binding constant of BSA to spherical AuNPs is higher than in the case of nanorod AuNPs. 
The spectroscopic data exhibited the molecular specificity of complex and feasible conformational 
changes of BSA on the surface of AuNP (Fig. 6) [71]. This data allows better understanding of the 
adsorption mechanism of proteins on the surface of NPs with the different morphologies applied 
in pharmacy or medicine. 
 
6. Protein corona induced NP aggregation 
Herein, we emphasize a feature that is not always addressed in NP in vitro and in vivo 
investigations, namely the colloidal stability of the NPs in biological fluids. Besides the protein 
corona formation, several groups have reported that in vitro NPs aggregate and form clusters of 
various sizes. Recent reviews are specifically focusing on the NP fate in biological systems and on 
their effects on dosimetry, cellular infiltrate and induced cytotoxicity [34, 72]. 
  
6.1. Exchange and/or the removal of the protecting coat 
NP aggregation has been determined for a broad range of NPs, including oxides (Ce, Fe, etc…) 
[58, 73-78], noble metals (Au, Ag) [55, 73, 77, 79, 80], semi-conductor quantum-dots [81] or 
polymers based NPs [82]. In these studies, the aggregate dimensions are characterized by light 
scattering (Fig. 7a and 7b), but their internal structure and morphology are in general not 
determined. Although, a precise description of NP aggregation is still unknown, it is well 
documented that the agglomeration of NPs in biological systems is deduced from the exchange 
and/or the removal of the protecting coat or from the adsorption of biological macromolecules 
(including proteins) at the NP surface [34, 59]. In the former case, the initial coating is not efficient 
to overcome the van der Waals interactions, leading to agglomeration and the sedimentation 
processes depend on various factors such as the nature and robustness of the coat [59]. In the latter 
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case, the adsorbed macromolecules are playing the role of physical bridges between NPs [34]. As 
illustrated in Figure 7c and 7d using TEM, the NP aggregation plays an pivotal role in the NP-cell 
interaction, and internalization.  
 
6.2. Reaction-diffusion processes 
 Reaction-diffusion processes are here responsible for the building of large disordered and non-
colloidal structures. In the more general context, “what the cell will see” in case of NP aggregation 
is not inorganic cores coated or not with proteins, but rather NP clusters with proteins and other 
biomacromolecules at their outer layers (Fig. 8). The hydrodynamic features of such aggregates 
are also drastically altered with respect to single NPs, and so will be their interactions with cells. 
Sedimentation effects of micron size aggregates have been put under scrutiny recently, in 
particular using the in vitro sedimentation, diffusion and dosimetry model developed to improve 
dose metrics methodologies [83]. This model finds that the doses administered to cells in vitro 
depend predominately on the NP dimension and on their densities. Because of gravity there is a 
concentration gradient of NPs that forms above the cell layers. In relevant cases it was explored 
that the effective concentration delivered to the cells can be much higher than the nominal one by 
a factor 10 to 100, initiating a bias in the cellular uptake and toxicity dose dependencies. In 
conclusion, it seems now well established that following the protein corona formation, other 
phenomena such as aggregation and sedimentation occur when NPs are dispersed in physiological 
conditions, and that the in vitro and in vivo interactions depend heavily on the NP colloidal state. 
Figure 8 illustrates the basic scenarios for aggregated and dispersed NPs in interaction with cells 
[59, 84].  
 
7. Protein aggregation  
NPs can speed up dramatically the rate of protein fibrillation or the formation of fibrils inducing 
amyloid diseases by diverse mechanisms. It was observed that NPs initiate protein aggregation at 
physiological pH, causing the induction of unfolded, amorphous protein-NP complexes, followed 
by large protein clusters [85]. The NP-initiated conformational changes of proteins very likely 
catalyze the formation of aggregate species and extension [85].  
It was shown that NPs such as copolymer NPs, cerium oxide NPs, quantum dots, and carbon 
nanotubes increase the formation of an essential nucleus for the formation of protein fibrils from 
human β2-microglobulin [86]. The detected shorter nucleation phase is heavily controlled by the 
concentration and NP chemistry. Proteins at the NP surface may experience different 
conformational changes and subsequent amyloid extension. It was also observed that Aβ fibril 
formation by TiO2 NPs is promoted. Indeed, NPs due to their high accessible area could shorten 
lag phase as the key rate-controlling phase of fibrillation [87]. Therefore, the impact of NP on 
amyloid aggregation depends on a number of parameters such as protein stability, intrinsic 
aggregation tendency, surface chemistry of NPs, pH of medium, and type of NP.  
 
7.1. Protein concentration 
It was revealed that β2-microglobulin adsorbs in the form of several layers on the NP surface. Such 
a locally enhanced protein concentration on the NP surface can facilitate oligomer extension. This 
and the shortened lag phase of aggregation mediate surface-derived nucleation enhancing the risk 
for toxic aggregated products and amyloid formations [86]. Surface Plasmon resonance (SPR) 
study revealed that β2-microglobulin adsorbs on the N-isopropylacrylamide/N-tert-
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butylacrylamide (NIPAM/BAM) NPs in the form of several layers. Therefore, it may suggest the 
aggregate formation in the presence of high concentration of protein [86, 88]. 
 
7.2. Surface charges, NP concentration and pH 
It was demonstrated that the thickness and the surface groups of the SPIONs can influence the 
kinetics of fibrillation of Aβ in vitro [89]. Concentration and surface modifications can play a dual 
impact on protein fibrillation. While, lower concentrations of SPIONs delayed the nucleation 
phase, its higher concentrations enhanced the rate of Aβ amyloid formation. With respect to 
surface charge, it was explored that the positively charged SPIONs can initiate fibrillation at 
dramatically low NP doses compared with negatively charged or uncharged SPIONs. This data 
indicated that in addition to the NP concentration, surface modification of NP also affects the 
protein conformation and corresponding formation of aggregated species. It was also reported that 
AuNPs initiate protein aggregation at physiological pH, causing the formation of unfolded, 
amorphous protein- NP complexes without embedded NPs (Fig. 9) [90].  
 
7.3. Intrinsic protein stability  
Indeed, proteins at the NP surface experience local destabilization inducing the formation of 
aggregate species and their extension. The impact of NP on amyloid aggregation heavily depends 
on a number of parameters such as protein stability and intrinsic aggregation tendency [91]. The 
aggregation process was explored in the absence and presence of copolymeric NPs with varying 
hydrophobic moieties. It was found that in the case of proteins with a very stable structure and low 
intrinsic aggregation tendency fibril formation is promoted by NPs. However, in case of low stable 
proteins and high intrinsic aggregation tendency, an inhibitory impact of amyloid fibril induction 
by NPs was determined (Fig. 10) [91]. Fluorinated NP was demonstrated to induce no Aβ40 
aggregation, whereas hydrogen substituted NPs promoted the conversion of Aβ40 from natively 
unfolded structure to β-sheet clusters [92]. Therefore, a valid association between the protein 
stability and the NP impact on the amyloid formation can be determined. It was shown that the 
native state of monellin protected it against aggregation [93].  
 
8. Amyloid disaggregation 
NP with substituted functional groups can be applied as potent ligands in preventing and curing of 
protein aggregation-derived diseases. The nucleation phase (rate-controlling step) is heavily 
dependent on surface modification of NPs. Generally, nanomaterials have very high surface energy 
and a strong tendency to each other [94]. Especially for those who have OH levels on their surface 
[95]. Therefore, by changing the functional levels of the nanomaterials by a variety of compounds, 
their agglomeration can be prevented. As a result, with the reduction of the growth phase, the 
nucleation stage increases [96]. 
 
8.1. Surface chemistry 
Amyloid clusters of Aβ42 were dissolved via the combined application of microwave irradiations 
and AuNPs. AuNPs with H-Cys-LeuPro-Phe-Phe-AspNH2 (Cys-PEP) as an attached peptide 
selectively binds to the Aβ aggregates, inducing the conjugated Au-NP-Cys-PEP. This peptide can 
recognize hydrophobic patches in the amyloid structure [97]. Polymer NPs with different 
hydrophobicity was revealed to delay fibrillation of Aβ [98]. It was indicated that these NPs 
influence primarily the nucleation phase of Aβ aggregation. The extension phase is not normally 
influenced by the NP. However, the extension phase was reported to be markedly dependent on 
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both the dose and surface characteristics of the NPs. SPR outcomes displayed that the adsorption 
of monomeric Aβ onto the NPs inhibits fibrillation. Moreover, it was revealed that fibrillation of 
Aβ can be reversed in the presence of NPs [98]. 
The adsorption of protein on the NP surface decreases the concentration of free protein in solution 
to initiate the aggregation process, extending the lag phase of aggregation. Additionally, the 
reduction of aggregation was observed by the equilibrium phase at the end of the fibrillation 
pathway (Fig. 11) [99]. LVFFARK (LK7) in the absence and presence of poly (lactic-co-glycolic 
acid) (PLGA) were designed to explore the amyloid β-protein fibrillation. LK7 was detected to 
inhibit Aβ42 fibrillogenesis in a concentration-dependent system. However, LK7@PLGA-NPs 
demonstrated dramatic inhibitory effect against Aβ42 aggregation [100]. It was also revealed that 
the fibril fibrillation can be retarded by inhibiting the nucleation and extension phases with a low 
concentration of functionalized quantum dots. The inhibiting impact of functionalized quantum 
dots on the fibril formation revealed that the functionalized quantum dots concentration was low 
[101]. 
Dendrimers with anti-aggregation features are regulated both by surface chemistry and surface 
group density. Dendrimers with cationic groups are more potent in inhibiting amyloid β-protein 
aggregation than surface hydroxyl groups and unmodified dendrimers [102]. A dopamine-
containing PEG-based polymer with high density was developed for the retardation of α-synuclein 
fibrillation [103]. Polymeric NPs can inhibit Aβ fibrillogenesis depending on their surface 
characteristics  [104].   It was found that polymeric NPs inhibit the amyloid extension due to 
negative surface charges. It was deduced that negative charge distribution van strength the 
stretching of Aβ42 molecules instead of the formation of amyloid aggregates [104].  
Green tea polyphenol epigallocatechin-3-gallate (EGCG) in the form of EGCG NPs (nano-EGCG) 
are more influential than molecular EGCG in retarding amyloid formation, destabilizing mature 
protein amyloids, and reducing amyloidogenic cytotoxicity  (Figure 12) [105]. It was reported that 
sugar-modified AuNPs inhibit intracellular polyglutamine-containing mutant protein amyloid 
elongation (Fig. 13) [106]. Sugar-terminated NP chaperones were observed to be more dynamic 
than molecular sugars in retarding protein fibrillation and reduced adverse effects (Fig. 14) [107]. 
It was demonstrated that fibrillation of HSA is rerated by adsorption on the chitosan- modified 
AgNPs [108]. Synergistic impacts of negatively charged hydrophobic NPs and (−)-
epigallocatechin-3-gallate was reported on inhibiting of Aβ elongation [109]. It was proposed that 
iminodiacetic acid-conjugated NPs (IDA-NP) can control Aβ42 amyloid formation and mitigate 
the cytotoxicity induced by Zn2+ [110]. Interaction of proteins with NP with high local protein 
density can play a pivotal role in amyloid formation. On the other side, protein adsorption can 
modulate the concentration of free protein in solution and consequently results in an extended lag-
time for protein cluster formation. Indeed, interaction of NPs and proteins could block the active 
sites for fibril induction and can mitigate free protein population in solution, thus inhibiting 
formation of fibrils. Certainly much more data are needed to define or foresee the effects of NPs 
on fibrillogenesis. 
 
9. NPs-protein corona and cytotoxicity  
Although NPs have immense application in industry, scientific knowledge and biomedical 
research, it can influence the biological nature of the cellular and subcellular levels. Distinct 
“protein corona signature” is formed by different protein component and is associated with the 
dimension and/or surface functional groups of the NPs. So, the induction of NP-protein coronas 
together with the biological reaction to these cellular biophysico-chemical mechanisms (i.e, 
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biotransformation, biodistribution and endocytosis,) and coronas (i.e., cytotoxicity, oxidative 
stress and inflammation) will be crucial for nanomedicine and nanotoxicology. The cytotoxicity 
of NPs is heavily modulated by their interactions with blood proteins. 
  
9.1. NPs interactions with plasma factors and proteins  
NPs interactions with plasma factors and proteins can influence the clearance and systemic adverse 
effects of the NP delivery system [111]. The adverse effects deriving from blood interactions are 
often ignored in the design and fabrication of NP-based systems for in vivo implementations. These 
toxicological threats are due to their small size as it can penetrate cell membranes and cross the 
various biological barriers and may reach the most sensitive organs [112]. Hazardous effects 
include protein denaturation induced by the large accessible area of NPs and DNA breaks in human 
cells induced by carbon nanotubes [113]. The NP-bound blood proteins can affect the immune 
system by stimulating immune cell reactions. Moreover, protein corona considerably influences 
interactions between NPs and cells through different activation of pathways along with 
internalization. For this purpose, in order to study the level of toxicity of NPs and its effects on 
cells, computational methods are used in addition to experimental methods. The powerful 
computing software such as the quantitative structure–activity relation (QSAR) is emerging. In 
these applications, there is a basic condition that most nanomaterials with comparable physical 
and chemical properties (size, zeta potential, particle surface area, moles of particles, and protein 
density) have almost the same biological activity. For example, Gajewicz, Schaeublin, Rasulev, 
Hussain, Leszczynska, Puzyn and Leszczynski [114] developed a nano-QSAR model for the 
toxicity of 18 kinds of metal oxide NPs for keratinocyte (HaCaT) cell line, which is a common 
model for facing NPs with skin. Also, Manganelli, Leone, Toropov, Toropova and Benfenati [115] 
designed a QSAR model that accurately predicts the human embryonic kidney cells (HEK293) 
response in the presence of 20 to 50 nm silica NPs. In another study based on the QSAR model 
and the 7 types of oxide NPs, it was shown that increasing the measured properties of NPs, 
especially the nanoparticle network model, the dosage, the enthalpy of formation, the exposure 
time and the hydrodynamic size, could increase the prediction level of the model by more than 
90% [116]. 
The greater surface area of NPs results in their high chemical activity and subsequent enhanced 
reactive oxygen species (ROS) production causing oxidative stress, inflammation [117, 118]. The 
mechanism of NP-induced cytotoxicity caused by non-soluble metal oxide NPs are still not clear, 
but reports suggest that these NPs stimulate oxidative stress, genotoxicity and immunotoxicity 
[119]. Gold NPs are used for cancer diagnosis and treatment [120], but it has been seen that gold 
NPs exert toxicity through the induction of oxidative stress and mitochondrial damage [121]. From 
all this, we inferred that the formation of NP-protein coronas significantly influence the 
immunological response by the physiochemical surface features of the NP and it should be 
addressed in future works by investigating the protein distribution and exploring in vitro and in 
vivo responses. 
 
9.2. The impact of NPs-protein corona on cytotoxicity  
As mentioned, the NPs via a disconnection of the totality of plasma membrane, mitochondrial 
collapse and nucleus injury may cause cell death (Fig. 15) [122], which can be greatly reduced by 
the physicochemical features of the protein corona like inaccessibility to the surface, the 
modification in the surface charge of NPs, etc. and its progression from soft to hard condition with 
low dynamic exchange in biological conditions [123]. It is clear from the data of figure 15 that the 
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protein corona significantly reduces the absorption of NPs by cells. While corona protein surface 
modification can reduce the absorption of nanomaterials. In particular, absorption suppression is 
visible for HSAsuc-coated NPs. While the presence of ethylenediamine in the protein corona can 
increase the cell wall uptake compared with the HSA native. However, intracellular penetration is 
also significantly reduced in comparison with the native group, which may be due to electrostatic 
interactions between NPs and cell surface. Indeed, with the creation of corona protein on NPs, the 
immune response to the NPs has altered and NPs become more biocompatible to the human body, 
whereas the protein corona increases the targeting and delivery of NPs in some cases. Since the 
toxicity of NPs generally arises from the contact with the membrane cells [124], creating a coating 
such as corona protein can help eliminate this problem and increments the NPs safety. In this 
respect, some research has shown that the toxicity of graphene oxide nano-sheets by FBS and BSA 
has been intently decreased due to the prevention of interface between NPs and cells (Fig. 16) 
[125, 126]. 
Their outcomes displayed that protein corona decrements the cytotoxicity through a remarkable 
careless of the graphene and membrane lipid contact and a decrease of the accessibility level area 
of graphene oxide. These findings provide different visions into the physical interaction and 
potential offend between NPs and cell membranes. Also, experiments showed that cells exposed 
to silica NPs without corona protein (HSA) had a developed degree of adherence to the cell 
membrane and larger permeability [127]. Besides, Yin, Chen, Casey, Ke, Davis and Chen [128] 
exhibited that the covering of zinc oxide NPs with corona protein decreases their cytotoxicity into 
skin fibroblasts and hepato-carcinoma human. Another study showed that the usage of corona 
protein as a covering of silver NPs reduced cytotoxicity by affecting cell surface receptors, whereas 
increasing the intracellular uptake of silver NPs [129]. Along with, it was shown that silver NPs 
prepared with carbohydrate covering shared with corona proteins created very low cytotoxicity in 
neuron-like cell line and a hepatocyte cell line compared to carbohydrate-based silver NPs [130]. 
Despite the high toxicity of carbon nanotubes, Ge, Du, Zhao, Wang, Liu, Li, Yang, Zhou, Zhao 
and Chai [131] and De Paoli, Diduch, Tegegn, Orecna, Strader, Karnaukhova, Bonevich, Holada 
and Simak [132] confirmed that the binding of blood proteins like albumin, histone, etc. to CNTs 
has greatly reduced their cytotoxic effects on umbilical vein endothelial cells and platelets. 
Although, reducing the NPs cytotoxicity due to decreased cellular connection and uptake by 
corona protein have been reported, this reduction can be considered as a negative point when using 
NPs for drug transfer into cells [125]. For instance, Ritz, Schöttler, Kotman, Baier, Musyanovych, 
Kuharev, Landfester, Schild, Jahn and Tenzer [133] revealed that NPs enveloped with the apo-
lipoproteins ApoA4 or ApoC3 significantly declined the cellular uptake into human mesenchymal 
stem cells, while in the same experiment, it was shown that the covering of NPs with ApoH 
increased the cellular uptake. Accordingly, the superficial adjustment process by corona proteins 
requires to be intently noticed and optimized realize for the greatest therapeutic effects. 
The interface between NPs and corona protein might decrease systemic toxicity. This scenario, 
similar to previous toxicity, is seriously reliant on the inherent level of NPs such as the creation of 
ROS owing to surface chemical activity [134]. The corona protein can augment the safety of NPs 
predominant materials with semiconductor properties by prohibiting the output of ROS. On this 
basis, Tenzer, Docter, Kuharev, Musyanovych, Fetz, Hecht, Schlenk, Fischer, Kiouptsi, Reinhardt, 
Landfester, Schild, Maskos, Knauer and Stauber [74] declared that uncovered silica NPs had a 
substantial hemolytic effect on red blood cells, whereas the blood cells were protected from 
destruction by the NPs due to the presence of corona protein. In addition, zinc oxide NPs are an 
obvious fabricator of ROS due to their pristine surface, but the presence of a corona protein 
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prevents this occurrence [128]. Also, in vitro studies offered that AuNPs performance as cytotoxic 
factors are related to an increment in ROS in human liver hepatocellular carcinoma cells, whereas 
AuNPs treated with corona proteins derived lung fluid were not toxic to human hepatoma cell line 
[135]. In concurring with this experiment, [22] showed that the use of corona protein like HSA 
and human plasma protein as a coating of AuNPs can moderate the cytotoxic effects of ROS and 
uptake cellular of NPs on hepatocyte cells. Nevertheless, corona proteins occasionally increase the 
cytotoxicity of a NPs due to protein denaturation with alterations of constancy and structural. The 
greatest important examples in this field are the contact of AuNPs with fibrinogen proteins as 
corona protein in the blood causes inflammatory responses when they are in interface with the 
leukocyte receptor MAC-1 [136]. As well as, the unwanted changes of tubulin protein as corona 
protein in the presence of titanium dioxide NPs is another example that reduces the ability of 
tubulin polymerization [137]. In conclusion, exploring and realizing the adverse effect of 
nanostructure-based substances treated with protein coronas is a serious assay toward controlling 
their cell uptake and subsequent oxidative stress and toxic outcomes (Fig. 17). 
 
10. Clinical application of protein corona-NP 
As mentioned, NPs have a low stability and high systemic toxicity or cytotoxicity to the cells due 
to its high free surface energy. Therefore, biomolecules such as corona protein are used to increase 
the stability and decrease the toxicity or cytotoxicity of NPs. In addition, based on the information 
obtained from papers, corona protein can be very effective in targeting NPs for drug delivery and 
imaging. 
 
10.1. The impact of NPs-protein corona on drug delivery  
One of the most important questions in the field of NPs cellular uptake is to increase their uptake 
with specific targets. Nonspecific uptake has been always a random process, whereas the specific 
uptake of NPs into a cell depends on cell surface membrane receptors and functional agents on the 
NPs. In this regard, several studies have shown that corona protein is highly effective in the 
targeted uptake of NPs and the stability of NPs due to preventing from renal filtration [138], but 
the key challenges of NPs in the body are the presence of corona protein compounds in the blood 
plasma, which can change the nature of the activity of NPs [139] and cause lag drug release by 
prohibiting drug diffusion via the matrix [140] along with decreasing of the burst effect [141]. 
Whereas corona protein can increase the loading capacity of a drug like a sponge as well as control 
the release time of the drug by simultaneously loading multiple drugs, and photothermal and 
photodynamic substance for cancer treatment [142]. Accordingly Qi, Yao, He, Yu and Huang 
[143] developed dextran–chitosan NPs coated with BSA along with doxorubicin that in addition 
to reducing the cytotoxicity, increasing the anti-tumor effect of doxorubicin and survivability of 
mice. However, Kah, Chen, Zubieta and Hamad-Schifferli [144] showed that protein corona 
despite its positive effect on the release of doxorubicin drug in the target cell, may have undesirable 
effects on gene-dependent therapies due to reduced release of genetic compounds in cells. In 
contrast, Kummitha, Malamas and Lu [145] showed that the corona proteins application on siRNA 
lipid NPs results in the improvement of the siRNA delivery in the body due to prevent non-specific 
association of serum molecules. In another study displayed that the use of lipid NPs coated with 
HSA in gene delivery to treat breast cancer cells was much more effective than control groups 
[146]. Generally, Cifuentes-Rius, de Puig, Kah, Borros and Hamad-Schifferli [147] demonstrated 
that the release rate of genetic compounds such as DNA loaded on the NPs could be modified by 
changing the type of corona protein. Analogously, Caracciolo, Cardarelli, Pozzi, Salomone, Maccari, 
Bardi, Capriotti, Cavaliere, Papi and Laganà [148] revealed that the use of vitronectin-integrin as a 
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corona protein on lipoplexes NPs made of 1,2-dioleoyl-3-trimethylammonium propane and DNA, 
increases the cellular uptake of nanoparticles in HEK 293 and MDA-MB-435s cell lines by up to 
twice as much as the control group. They also showed that corona protein increase the survival of 
nanoparticles in the blood and reduce toxicity. In this line, Digiacomo, Cardarelli, Pozzi, Palchetti, 
Digman, Gratton, Capriotti, Mahmoudi and Caracciolo [149], in a cellular model, were able to 
cellular uptake of the provided NPs with the higher performance in HeLa cell lines, by developing 
liposome NPs coated with apolipoprotein as protein corona derived from human plasma. It has 
been shown in this study that apolipoprotein as a protein corona induces NPs into target cells via 
macropinocytosis to clathrin-dependent endocytosis. 
In the following, Schäffler, Sousa, Wenk, Sitia, Hirn, Schleh, Haberl, Violatto, Canovi and 
Andreozzi [150] declared that the AuNPs coated with albumin represented more accumulation in 
the lungs, spleen and brain in comparison with the control AuNP. Using this finding, it is possible 
to overcome the pulmonary diseases like tuberculosis, or to prevent bloodshed and brain diseases 
by crossing the blood-brain barrier. Without the use of targeting agents that corona protein pattern 
affects them, the application of corona protein decreases the effect of the NPs containing cancer 
drug [151]. For instance, Yallapu, Chauhan, Othman, Khalilzad-Sharghi, Ebeling, Khan, Jaggi and 
Chauhan [152] showed that the change in the corona protein from HSA to Apolipoprotein-E in the 
NPs can carrier the drug towards the kidney and the liver, despite the presence of cancer receptors 
(Fig. 18).  
On the other hands, Rastogi, Kora and Arunachalam [153] demonstrated that gold NPs coated with 
BSA corona protein are very suitable carriers for transferring antibiotics like gentamicin, 
neomycin, etc. to the target tissue to eliminate gram positive and gram-negative bacteria compared 
to control groups. NPs containing bio-corona proteins may cause the inflammasome in 
macrophages, which will motivate the production pro-inflammatory cytokines cascade. Hence, 
they can be effective in providing vaccines. In this field, the use of coronavirus antigens in birds 
as corona proteins has improved vaccination compared to common vaccination [154]. Inoculation 
the AuNPs coated with virus-like particles as corona protein caused the elevated lymphatic antigen 
transfer, enhanced cell response, and decreased infection related signs in an avian model with 
coronavirus infection compared to insemination with free proteins. In the next study, Chang, 
Diambou, Kim, Wang and Champion [155] indicated that ovalbumin NPs coated with adjuvants-
flagellin and immunoglobulin corona proteins derived from salmonella (disease agent) and mice 
(host representative), respectively, increased the cells immune response in mice. 
 
10.2. The impact of NPs-protein corona on cancer therapy  
For the treatment of cancer, which is one of the most lethal diseases, the chemotherapy is still the 
most widely used treatment method despite the many disadvantages such as high toxicity to non-
target cells, non-specificity, and so on. Accordingly, nanomedicine by introducing NPs coated with 
drugs and biological compounds such as corona proteins has been used to treat the cancers more 
appropriately, with reduced cytotoxicity and increased drug targeting in clinical and laboratory 
levels. In this field, Caracciolo [156] explained that the use of NPs coated with protein corona such 
as protein coated liposomes could be a desirable option for chemotherapy activities in transferring 
drug to target cells without causing toxicity in other tissues and cytotoxicity due to accumulation 
of inorganic NPs. For example, Doxil® was originally approved for Kaposi’s sarcoma (1995) and 
later for breast cancer (1999) and ovarian cancer (2003). However, chemotherapy drugs are usually 
limited within the liposome. As a result, they play a minor role in tumor cells. Therefore, attention 
to metallic NPs, despite specific toxicities, increased to synchronize therapeutic activities such as 
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chemotherapy, radiotherapy, and imaging. For instance, Chunfu, Jinquan, Duanzhi, Yongxian, 
Yanlin and Jiajü [157] using HSA corona protein as a coating on magnetic NPs, in addition to 
reducing the side effects, increased the 188Re radioisotop loading capacity in cancer cells for cancer 
treatment by radiotherapy. Furthermore, Quan, Xie, Gao, Yang, Zhang, Liu, Lin, Wang, Eden and 
Lee [158] expanded HSA-coated iron oxide NPs with anti-cancer drug (doxorubicin) which corona 
protein due to increase of stability and higher targeting contributed to the further translocation of 
doxorubicin across the breast cancer cell membrane to its accumulation in the nucleus. Meanwhile, 
Xing, Bhirde, Wang, Sun, Liu, Hou and Chen [159] explained that hollow iron oxide NPs coated 
with HSA had the greatest potential for transferring doxorubicin drug to cancer cells of resistance 
to treatment compared to free NPs, and can simultaneously transport multiple drugs to the target 
cell and release them during treatment slowly along with greater power and clarity of target tissue 
imaging. In this line, Hajipour, Akhavan, Meidanchi, Laurent and Mahmoudi [160] showed that 
Superparamagnetic zinc ferrite spinel-graphene nanostructures coated with HP corona protein can 
have a significant effect on the treatment of cancer cells and the toxicity associated with the use of 
NPs by inducing the production of ROS in the target cell. Also, Arvizo, Giri, Moyano, Miranda, 
Madden, McCormick, Bhattacharya, Rotello, Kocher and Mukherjee [161] illustrated that with the 
use of corona protein along with hepatoma-derived growth factor on AuNPs, the removal of 
ovarian cancer cell lines has been remarkably increased. Moreover, by using albumin as a coating 
for lipid NPs containing Docetaxel, it was provided more transfer of the drug from the blood-brain 
barrier, increase apoptosis in cancerous cells, and drugs accumulate at the experimental glioma 
site [162]. Furthermore, Akrami, Khoobi, Khalilvand-Sedagheh, Haririan, Bahador, Faramarzi, 
Rezaei, Javar, Salehi and Ardestani [163] developed a magnetic iron oxide NPs with an anticancer 
drug as curcumin coated with HP corona protein that reduced the growth and proliferation of breast 
cancer cells compared to free NPs. Since the NPs less than 5 nm exhibit the lowest toxicity due to 
fast filtration of the kidneys, AL-Jawad, Taha, Al-Halbosiy and AL-Barram [164] produced small 
AuNPs (<5 nm) coated with BSA to increase stability (with increasing particle size) which in 
addition to increasing photothermal therapy by laser irradiation in cancer cell lines, showed the 
least toxicity (up to 70%). Similarly, Hai, Piraux, Mazario, Volatron, Ha-Duong, Decorse, Lomas, 
Verbeke, Ammar and Wilhelm [165] exhibited that the maghemite NPs coated with HSA corona 
protein eliminated cancer cell lines by photothermal therapy with very low toxicity. Moreover, 
Azizi, Ghourchian, Yazdian, Dashtestani and AlizadehZeinabad [166] showed that the CuNPs 
coated with BSA corona protein had the lowest toxicity and the highest inhibitory power to breast 
cancer cells up to 90%. Likewise, Azizi, Ghourchian, Yazdian, Bagherifam, Bekhradnia and 
Nyström [167] with the use of albumin corona protein on the silver NPs was able to inhibit the 
growth of breast cancer cells by producing more ROS, delaying release of the drug, and the 
stability of NPs compared with free NPs. In addition, they showed that the of silver NPs coated 
with HSA accumulated in the cancer cells, despite being less toxicity than the control group [167]. 
In line with the medication, Yeo, Joshua, Cheah, Neo, Goh, Kanchanawong, Soo, Thong and Kah 
[168] reported that the use of corona protein for simultaneous application of doxorubicin drug, 
photodynamic and photothermal agents has increased drug uptake and the removal of oral cells 
carcinoma by up to 98.7% with the least cytotoxicity due to minimal drug intake (Fig. 19). In other 
studies showed that the application of corona protein like fetal bovaine serum or HSA on AuNPs 
and iron NPs for simultaneous loading of the cancer drug and photothermal materials could reduce 
the dose of the drug, despite its an increase in the tumor after 6 hours of injection [169, 170]. 
However, despite the presence of gold nanorods containing drugs in other tissues such as the liver 
and spleen, it did not have toxic effects during the trial period (39 days). In the following, the 
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application of hyaluronic acid and BSA corona proteins on the surface of super paramagnetic iron 
oxide NPs in addition to increasing the stability of NPs resulted in the appropriate transfer of 
paclitaxel to cancer cells compared to the free NPs [171]. In general, due to the conformity of the 
nature of corona protein to the body's biological conditions, the application of these biological 
components can increase the amount of NPs present in the body and improve blood circulation 
time. For instance, a 6 times increment of half-time was introduced by Peng for BSA-coated NPs 
compared to free NPs [140]. In this line, Guo, Sun and Zhang [172] described that lipid coated 
AuNPs, after being injected into the blood and combining with the corona protein derived from 
blood plasma, were more likely to accumulate and survive in the liver cancer cells. 
 
10.3. The impact of NPs-protein corona on imaging  
The imaging by NPs is one of the most important methods used in the field of nano-medicine to 
reduce the error rate in detecting the location of a complication. But, in the first stage, uniform 
distribution in the body without systemic toxicity or cytotoxicity, in the second phase, focusing in 
the target tissue with sustainability, and in the final stage of imaging clarity are NPs challenges 
which are presumed to overcome by the creation of corona protein on NPs. In this regard, the 
negative effect of corona proteins like HSA on the nature of NPs imaging was initially investigated 
and showed had no negative effect on MRI imaging, whereas increasing the capacity of the 
imaging labels. Accordingly, Kresse, Wagner, Pfefferer, Lawaczeck, Elste and Semmler [173] and 
Högemann-Savellano, Bos, Blondet, Sato, Abe, Josephson, Weissleder, Gaudet, Sgroi and Peters 
[174] declared that the use of transferrin as a corona protein along with thioether on para-magnetic 
iron oxide NPs increases the accumulation of these particles in breast cancer cells due to the 
presence of more receptors of transferrin on them. Despite showing promising contrast-enhancing 
effects transferring compounds are removed rapidly by the reticuloendothelial system. Hence, the 
use of these compounds does not appear to be desirable in imaging. While, the use of on para-
magnetic iron oxide NPs with HSA protein coating has increased the nuclear magnetic resonance 
imaging of the liver with a very low dose [175]. Then it was shown in the next researches that with 
the use of HSA corona protein, the stability of a magnetic NPs containing the imaging label has 
increased by up to 90% (up to 72 hours), and due to the high concentration of NPs-labeled in the 
target tissue a higher resolution of imaging was obtained (Fig. 20) [157]. Moreover, Huang, Xie, 
Chen, Bu, Lee, Cheng, Li and Chen [176] exhibited that the use of HSA corona protein on MnO 
NPs along with 64Cu radioisotope leads to more prominent T1 contrast, 5 times transverse 
reflaxivity r2 and an increase in imaging. Similar to this study, Xie, Chen, Huang, Lee, Wang, 
Gao, Li and Chen [177] showed that the use of albumin coverage along with dopamine and 64Cu 
labels for imaging with iron oxide NPs increased transparency in imaging and more drug delivery 
to target cells with very low toxicity (Figure 18). Huang, Wang, Lin, Wang, Yang, Kuang, Qian 
and Mao [178] also explained that the iron NPs coated with corona protein derived from milk 
(casein) leading to much greater biocompatibility, stability and more accurate imaging of the breast 
cancer tissue. Casein protein increased the MRI contrast by enhancing the ability of T2 and 
developing the 2.5-fold transverse reflaxivity r2 compared to free NPs in 3 tesla. In addition, 
Nigam, Waghmode, Louis, Wangnoo, Chavan and Sarkar [179] developed graphene quantum dot 
with HSA particles and pancreatic cancer drugs that enhanced the imaging up to %14 and 
accumulation of anticancer drugs (gemcitabine) in tumors resistant to treatment. 
As mentioned in the above studies, serum proteins as corona proteins are very useful for drugs 
delivery and imaging because of the increased stability of NPs and the possibility of targeting 
them. However, due to the extremely difficult and limited control of corona protein in bio-
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condition [174], their harmfulness in most targeting [152] and inaccessibility of the cell in the most 
cases [139], it leads to reticuloendothelial agglomeration that can cause unpredictable activity. On 
the other hand, the pathological alteration in diverse diseases can cause the formation of different 
protein corona in bio-condition. Thus, the notion of a “personalized protein corona” will be a 
contributing agent for clinical applications that are still ambiguous [160]. 
 
10.4. The impact of NPs-protein corona on detection  
Non-invasive diagnosis and screening of diseases is a growing need in the medical field. In this 
regard, the use of nanoparticles can, in addition to increasing the accuracy of detection, reduce the 
speed and cost of detection. However, proteins in the blood plasma as corona proteins can be 
effective on the diagnostic activities via changing the physico-chemical properties of nanoparticles 
[180]. For example, it has been shown that AuNPs (~100 nm) containing citrate ligands with 
human immunoglobulin G (IgG) as a protein corona coating can improve the sensitivity of prostate 
cancer diagnosis by up to 50% [181]. Increasing human IgG levels as protein corona in the blood 
is associated to autoantibodies produced from prostate cancer, which is part of immune defense 
against the tumor. Also, Caputo, Papi, Coppola, Palchetti, Digiacomo, Caracciolo and Pozzi [182] 
found that human plasma coating on liposome NPs (~135 nm) in pancreatic cancer patients had a 
higher accumulation of protein corona than healthy people. They showed that the accuracy of 
detection of pancreatic cancer through the protein corona is improved by up to 90% versus the 
control group. Therefore, the interaction of protein corona in the blood plasma with NPs creates 
unique patterns based on human characteristics [183]. Patterns of protein corona produced by a 
cancerous patient are different from healthy subjects, which can be used to diagnose cancer at the 
early stages of tumor formation. 
 
11. Opportunities and challenges 
Exposure of the human body to NP can happen through several routes such as: inhalation, 
ingestion, injection or epidermal contact.  Protection of NPs is vital, because in some cases even 
lower concentrations NPs initiate adverse effects on the biological system [184-186]. Corona 
formation results in mitigating the cytotoxicity of NPs, because the bare NP surface is active until 
the NP are cleared through phagocytosis [19, 32]. 
It is now well established that once in contact with biological systems nanomaterials acquire new 
biological features due to protein corona. The protein corona structure may differ depending on 
the physicochemical properties of NPs, including sizes, surface charges, morphologies, and 
aggregation states. Therefore, the different NPs incubated with plasma proteins from protein 
coronas with varying compositions giving rise to different protein corona structures and biological 
interactions, and outcomes. These changes, in turn, impact the biological responses of NPs, 
including their pharmacokinetics, biodistributions, and therapeutic results. Herein, we reviewed 
this concept along with recent advances in this domain, with a particular attention focused on 
conformational changes of adsorbed proteins.  
On the other side, the protein corona plays an essential biological role by coating the NPs and 
masking the accessible sites of the nanomaterials. Therefore, it is important to determine the 
relationship between chemical functionalities of NPs and their biological activities, for example, 
in NP-induced targeted drug delivery systems and medicinal applications [187]. Additionally, NPs 
can destabilize the structure of adsorbed proteins and vice versa, and subsequently change the 
function of proteins and colloidal stability of NPs [188]. 
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 Exploring the basic information regarding the protein corona structure, NP-induced protein 
aggregation and disaggregation is crucial since the form and character of the nano-bio interphase 
defines the fate of NPs, what impacts the biological responses of the protein -NP complexes. 
 
12. Conclusion 
As indicated in Section 6, the inevitable coating of nanomaterials by protein corona after injection 
should be accepted and exploited. However, one of the main challenges for the application of 
nanomaterials within the field of nanomedicine is the complications deriving from the protein 
corona adverse properties. To this end, based on the topics of Sections 2 to 5, we need to have a 
profound understanding of the formation of protein corona and its effects on biological interactions 
based on the chemical composition, size, shape and surface properties of nanomaterials. 
Depending on the protein corona structural changes induced by nanomaterials surveyed in this 
perspective, one can deduce that there is a high necessity for a systematic remedy for protein 
corona induced complications. But it should be kept in mind that the correct binding of the protein 
groups can have favorable biological responses for medical applications such as target delivery 
and uptake, larger circulation time, activation of immune responses, evacuation of pathologic 
biomolecules and more importantly, reducing cytotoxic effects of nanomaterials. However, 
precautions should be taken to ensure that the functional levels of the nanomaterials are not filled 
up to prevent interactions between cell receptors and nanomaterials. Such advances in the field 
will not only minimize the contradictions in the nanotoxicology perception, but it could also bridge 
the gap between in vitro and in vivo outcomes, what could accelerate the application of 
nanomedicine techniques in clinics when assuring their safety. 
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Table 1. The cause of non-specific binding of corona protein to nanoparticles [189].  
 NP parameter Observed effect  
1 NP size Bigger size, larger degree of protein coverage 
  Smaller size increases corona thickness and decreases conformational 
change 
  Evolution of composition and relative abundance of adsorbed proteins 
2 NP shape Higher protein adsorption onto nanorods compared to nanospheres 
 NP surface Charge Charge affects composition of formed protein corona 
  More highly charged surfaces increase protein conformational changes 
  Protein conformation: positive > negative > neutral 
  Charged particles have higher cell internalization and faster opsonization 
rates than electrically neutral particles; positively charged NPs are 
incorporated by cells in higher numbers and faster than negatively charged 
NPs 
3 Hydrophobicity 
 
Increase adsorbed protein quantity and qualitatively change obtained 
protein adsorption patterns 
  Increase affinities of biomolecules 
  Increase protein conformational changes 
  Are opsonized more quickly than hydrophilic NPs 
4 Smoothness/roughness 
 
Surface roughness greatly minimizes repulsive interaction and influences 
the amount of protein, but not the protein identity 
 
Table 2. The impact of NP size on the behavior of proteins upon adsorption onto the NP surface. 
NP Size 
(nm) 
Technique Protein Outcomes Refs 
SiO2 4, 20 and 100 
CD and UV-Vis Lysozyme Denaturation of 
adsorbed lysozyme 
[190] 
N-isopropylacrylamide 
(NIPAM): N-tert-
butylacrylamide 
(BAM) copolymer 
70 and 
100 
ITC HSA The equilibrium 
association constant 
was not correlated with 
the dimension and 
composition of NPs. 
[191] 
SiO2 
11, 36 
and 150 
Centrifugation 
assays and CD 
Subtilisin 
Carlsberg 
(SC) 
A typical Langmuir 
adsorption model as 
well as conformation 
changes. 
[192] 
SiO2 
4, 15, 35 CD Cyt C Little change of 
structure of cyt C, 
albeit with slightly 
larger changes for cyt 
C on larger NPs. 
[193] 
SiO2 20, 30, and 100 
Label-free liquid 
chromatography MS  
Plasma 
proteins 
Absorption of 37 % of 
proteins 
[194] 
Negatively charged 
lipid-based NPs 
(liposomes) 
27 and 
103 
NMR Ubiquitin Lifetime (τex) < 
molecular tumbling 
times (τR) for 103 nm 
liposomes and >τR for 
27 nm liposomes 
[195] 
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SiO2 NPs 
6,9,15 NMR and CD Human 
carbonic 
anhydrase 
Larger NPs mediated 
larger denaturation of 
the protein secondary 
structure 
[196] 
 
Table 3. The influence of pH of medium on the adsorption behavior of proteins. 
NP pH Technique Protein Outcomes Refs 
SiO2 2-12 X-ray scattering (SAXS) Lysozyme 
Protein binding at 
different pH is 
irrespective of the 
ionic strength 
[197] 
SiO2 2–11 UV-Vis Lysozyme and ß-lactoglobulin 
Repulsive protein-
surface and protein–
protein interactions. 
[198] 
SiO2 5-9 
Small-angle neutron 
scattering (SANS) 
and UV–vis 
Lysozyme Colloidal NPs existing with increasing pH [199] 
SiO2 5-11 DLS and SANS Lysozyme and BSA 
The colloidal stability 
of NPs in the presence 
of lysozyme and NP 
agglomeration in the 
case of BSA when pH 
approaches its 
respective IEPs. 
[49] 
Micelles encapsulating 
BSA and streptavidin 2-12 UV-Vis BSA 
NP released the 
proteins in neutral and 
basic pH 
[200] 
Fe3O4 NPs-capped 
mesoporous silica 2-12 UV-Vis 
Bone 
morphogenetic 
protein 2 
pH-responsive 
controlled release 
system 
[201] 
 
 
 
Table 4.  The impact of surface functionalization of NPs on the adsorption behavior of proteins. 
NP groups Technique Protein Outcomes Refs 
Magnetic 
NPs 
(MNPs) 
Positive 
polyethyleneimine 
(PEI-MNPs) and 
(b) negative 
poly(acrylic acid) 
(PAA-MNPs) 
DLS 
Cell 
culture 
medium 
proteins 
Production of large 
MNP-protein aggregates [202] 
Maghemite 
(Fe2O3) NPs 
Citrate ions, 
poly(acrylic acid) DLS, TEM 
Serum 
proteins 
NP aggregation initiated 
by protein corona 
formation 
[58, 
59] 
Maghemite 
(Fe2O3) NPs 
Phosphonic acid 
PEG copolymers 
TEM, DLS, 
Quartz crystal 
microbalance 
(QCM) 
relaxometry, 
Serum 
proteins 
Particle devoid of 
observable protein 
corona 
[64, 
67, 
68] 
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Enshroudin
g polymer-
coated NPs 
PEG FCS HSA and fibrinogen 
Adsorbed HSA 
molecules contrary to 
fibrinogen are buried 
[203] 
Fe–Pt NPs Carboxyl, amino and both FCS HSA 
No effect of surface 
modification on protein 
corona formation 
[204] 
CdSe/ZnS 
quantum 
dots 
Carboxyl, amino 
and both FCS HSA 
No effect of surface 
modification on protein 
corona formation 
[204] 
Au and Ag 
nanoclusters 
Carboxyl, amino 
and both FCS HSA 
No effect of surface 
modification on protein 
corona formation 
[204] 
Iron oxide 
NPs 
(SPIONs) 
Surface 
hydrophobicity 
Flow field-flow 
fractionation and 
ultracentrifugatio
n 
Human 
serum 
Increasing surface 
hydrophobicity results in 
formation of soft corona 
[205] 
AuNPs Polar and nonpolar groups ITC BSA 
Adsorption of BSA on 
AuNPs was primarily 
caused by electrostatic 
interactions. 
[52] 
AuNPs Citrate-coated NMR GB3 and ubiquitin 
Charge, Kb, and 
dimension of each 
protein determine the 
stoichiometry of protein 
adsorption 
[206] 
SBA-15- 
Native one SBA-
OH, aminated 
SBA-NH2, 
thiolated SBA-SH 
and carboxy-
terminated SBA-
COOH. 
CD HSA 
SBA-COOH mediated 
the conformational 
changes of HSA 
[207] 
AuNPs D, L, and racemic penicillamine 
Quartz 
microbalance 
platform 
transferrin 
Chiral surface of NP 
dictate the denaturation 
of transferrin 
[208] 
polystyrene 
NPs 
Poly 
(phosphoester)s ITC HSA 
Chemical structure itself 
plays a crucial role in 
interaction process. 
[209] 
polystyrene 
NPs 
Sodium dodecyl 
sulfate or Lutensol 
AT50 
 
ITC HSA 
surface chemistry 
markedly changes the 
protein binding affinity 
[210] 
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Figure 1. Protein corona structure mostly depend on the physicochemical properties of NPs such 
as size, shape, surface functional groups, and pH of medium. 
 
 
 
 
 
Figure 2. Adsorption of protein on larger NPs results in bigger conformational changes compared 
with interaction with smaller NPs. Hence the size can influence the kind of interactions between 
NP and proteins. 
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Figure 3. The pH-dependent denaturation of BSA after interaction with AuNPs. Different pH of 
medium induces different charge distribution on the protein surfaces and subsequent interactions 
and denaturation. 
 
 
 
 
 
Figure 4. The surface chemistry of AuNPs mediates the degree of NP-triggered conformational 
changes of cyt C. When gold nanoparticles are placed with positive, negative and neutral ligands 
adjacent to cytochrome C, the structure of cytochrome C changes with the shift in the ions of NPs. 
Protein maintains its structure with neutral ligands, but changes in the presence of other ions. 
Reprinted with permission from reference [51]. 
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Figure 5. Depending on the surface properties of NPs, proteins do not adsorb on NPs. Gold NPs 
incorporated with a double mixture of hydrophobic and hydrophilic thiolated ligand molecules 
have been shown to form a ligand shell with stripe-like domains of alternating 
hydrophobic/hydrophilic combination. These stripe-like domains have a characteristic thickness 
on the order of a single nanometer, leading to surface heterogeneities at similar scales as those 
found on proteins. Reprinted with permission from reference [52]. 
 
 
 
 
Figure 6. Different interactions with Au NPs and corresponding structural changes of BSA 
dependent on the variations in NP morphology. 
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Figure 7: a) Hydrodynamic radius 𝐷# versus time for 7 nm coated and uncoated iron oxide NPs 
in the cell culture medium supplemented with 10% heat-inactivated fetal bovine serum. For 
uncoated particles as well as for cliavist® NP aggregation occurs. Particles coated with polymers 
(e.g. poly(acrylic acid) and phosphonic acid PEG copolymers) remain disperse for several months 
and devoid of protein corona [64]. b) Same as in a) for 7 nm cerium oxide NPs (CeO2) coated with 
citrate and poly(acrylic acid) [84]. c) Transmission electron microscopy (TEM) images of 
lymphoblastoid cells treated with Cit–γ-Fe2O3 NPs for 24 h at [Fe] = 10 mM; c1) and c2) 
demonstrate NPs enclosed in an endosome and clusters, respectively. Bars are 2 µm in c) and 300 
nm in c1-c2) [59]. d) Same as in c) for lymphoblastoid cells incubated with PAA2K–γ-Fe2O3 NPs 
for 24 h at [Fe] = 10 mM; b1) exhibits NPs enclosed in 200 nm endosomes. Bars in d) are 2 µm 
and 300 nm in d1) [59]. 
 
 
Figure 8. Schematic representation of cell-NP interactions. Uncoated NPs aggregate in the 
presence of serum protein and are either internalized into endosomes in large quantities or sticking 
at the membrane. Polymer coated NPs in contrast are much less internalized and are located 
intracellularly in endosomes [59, 84, 211].  
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Figure 9. AuNPs initiate amyloid nucleation, causing the formation of protein aggregation without 
embedded NPs. Reprinted with permission from reference [90]. 
 
 
 
 
 
 
Figure 10. NPs accelerated amyloid nucleation of more stable protein 
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Figure 11. Protein adsorption on the NP surface result in small amounts of free protein in the 
solution. Thus, the binding process causes retardation of amyloid nucleation phase. Reprinted with 
permission from reference [99]. 
 
 
 
 
Figure 12. Nano-EGCG protects neuronal cells from the adverse effects of extracellular 
polyglutamine (polyQ) aggregates or protein aggregates by inhibiting their amyloid induction. 
Reprinted with permission from reference [105]. 
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Figure 13. Trehalose-modified AuNPs can play an inhibitory impact on intracellular 
polyglutamine-containing mutant protein amyloid elongation. Reprinted with permission from 
reference [106]. 
 
 
 
 
 
Figure 14. Sugar-modified NP inhibits the induction of protein amyloid and decrease the adverse 
effects of aggregated proteins on the cells. Reprinted with permission from reference [107]. 
 
  
38 
 
 
 
Figure 15. Adsorption of HSA on dihydrolipoic acid-coated quantum dots (DHLA-QDs) affected 
adhesion velocity to the cell membrane and infiltrate outcome for HeLa cells.  (A) Adsorption of 
different HSA proteins onto DHLA-QDs. (B) Cells were treated with QDs in the absence or 
presence of different HSA proteins. (C) Quantification of NP uptake. Reprinted with permission 
from reference [122]. 
 
 
 
 
 
Figure 16. The cytotoxicity of graphene oxide was markedly reduced at cell culture medium. 
Reprinted with permission from reference [125]. 
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Figure 17. Possible uptake process and mechanisms of cytotoxicity induced by NPs and mitigated 
toxicity by corona protein in cells based on the metadata from several studies. 
 
 
 
 
Figure 18. Schematic illustration of NPs bio-diffusion with varying coatings. 
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Figure 19. Schematic representation of NPs construction and drug transfer with irradiation therapy 
in target cells. 
 
 
 
 
Figure 20. (a) Schematic illustration of the development of HSA-IO NPs. (b) Illustrative in vivo 
NIRF images of mouse inoculated with HSA-IONPs. Images were acquired 1 h, 4 h and 18 h post 
injection. (c) In vivo PET imaging outcomes of mouse inoculated with HSA-IONPs. Images were 
obtained 1 h, 4 h and 18 h post injection. (d) MRI images obtained before and 18 h post inoculation. 
Reprinted with permission from reference [157]. 
 
